Author: claimsbot

1. A job management framework, embedded as computer-executable instructions and data structures in a computer system, for managing operations executed by devices having potentially multiple distinct personalities, the job management framework comprising:
a set of hierarchically arranged content units comprising at least a first content unit at a first hierarchical level and a second content unit at second hierarchical level, and wherein the first hierarchical level is higher than the second hierarchical level;
a set of multilevel tickets identifying a set of properties to be applied by the job manager during execution of an operation; and
a job manager including executable instructions for performing the steps of:
merging a first ticket associated with the first content unit and a second ticket associated with the second content unit to generate merged settings applicable to at least the second content unit, wherein the merging is governed at least by a qualified inheritance rule wherein settings applicable to a set of second level properties that are specified within the first ticket are incorporated into the merged settings to the extent the second ticket does not specify settings for the set of second level properties; and
applying the merged settings to the second content unit.
2. The job management framework of claim 1 wherein each ticket comprises:
a set of ticket elements, wherein each ticket element specifies:
a level identifier specifying a level of a set of levels supported by the ticket,
a property identifier, and
a setting value for a property associated with the property identifier.
3. The job management framework of claim 2 wherein the operation comprises generating displayable output.
4. The job management framework of claim 3 wherein the operation comprises generating printer output.
5. The job management framework of claim 4 wherein the level identifier is capable of designating a level from the set of levels including the second level, corresponding a page, and a first level corresponding to a document.
6. The job management framework of claim 5 wherein the set of levels further includes a third level, above the first level, corresponding to a job.
7. The job management framework of claim 2 wherein the set of levels includes distinct levels corresponding to: individual data elements, grouped data elements, and collections of grouped data elements.
8. A multilevel ticket for specifying property settings applicable to content associated with an operation performed by a computing system, the ticket comprising:
a set of ticket elements, wherein each ticket element specifies:
a level identifier specifying a level of a set of levels supported by the ticket,
a property identifier, and
a setting value for a property associated with the property identifier.
9. The multilevel ticket of claim 8 wherein the set of levels includes distinct levels corresponding to: individual data elements, grouped data elements, and collections of grouped data elements.
10. The multilevel ticket of claim 9 wherein the operation comprises generating displayable output.
11. The multilevel ticket of claim 10 wherein the operation comprises generating printer output.
12. The multilevel ticket of claim 11 wherein the level identifier is capable of designating a level from the set of levels including a page level and document level.
13. The multilevel ticket of claim 12 wherein the set of levels further includes a job level.
14. A method for completing an operation according to a set of multilevel tickets associated with a set of hierarchically arranged content units, comprising at least a first content unit at a first hierarchical level and a second content unit at second hierarchical level, and wherein the first hierarchical level is higher than the second hierarchical level, the method comprising:
merging a first ticket associated with the first content unit and a second ticket associated with the second content unit to generate merged settings applicable to at least the second content unit, wherein the merging is governed at least by a qualified inheritance rule wherein settings applicable to a set of second level properties that are specified within the first ticket are incorporated into the merged settings to the extent the second ticket does not specify settings for the set of second level properties; and
applying the merged settings structure to the second content unit.
15. The method of claim 14 wherein each ticket comprises:
a set of ticket elements, wherein each ticket element specifies:
a level identifier specifying a level of a set of levels supported by the ticket,
a property identifier, and
a setting value for a property associated with the property identifier.
16. The method of claim 15 wherein the set of levels includes distinct levels corresponding to: individual data elements, grouped data elements, and collections of grouped data elements.
17. The method of claim 15 wherein the operation comprises generating processed output based upon settings information provided by the ticket.
18. The method of claim 15 wherein the operation comprises generating displayable output.
19. The method of claim 18 wherein the operation comprises generating printer output.
20. The method of claim 19 wherein the level identifier is capable of designating a level from the set of levels including the second level, corresponding a page, and a first level corresponding to a document.
21. The method of claim 20 wherein the set of levels further includes a third level, above the first level, corresponding to a job.
22. A computer-readable medium having computer-executable instructions for completing an operation according to a set of multilevel tickets associated with a set of hierarchically arranged content units, comprising at least a first content unit at a first hierarchical level and a second content unit at second hierarchical level, and wherein the first hierarchical level is higher than the second hierarchical level, the computer-executable instructions facilitating performing the steps of:
merging a first ticket associated with the first content unit and a second ticket associated with the second content unit to render merged settings applicable to at least the second content unit, wherein the merging is governed at least by a qualified inheritance rule wherein settings applicable to a set of second level properties that are specified within the first ticket are incorporated into the merged settings to the extent the second ticket does not specify settings for the set of second level properties; and
applying the merged settings structure to the second content unit.
23. The computer-readable medium of claim 22 wherein each ticket comprises:
a set of ticket elements, wherein each ticket element specifies:
a level identifier specifying a level of a set of levels supported by the ticket,
a property identifier, and
a setting value for a property associated with the property identifier.
24. The computer-readable medium of claim 23 wherein the set of levels includes distinct levels corresponding to: individual data elements, grouped data elements, and collections of grouped data elements.
25. The computer-readable medium of claim 23 wherein the operation comprises generating processed output based upon settings information provided by the ticket.
26. The computer-readable medium of claim 23 wherein the operation comprises generating displayable output.
27. The computer-readable medium of claim 26 wherein the operation comprises generating printer output.
28. The computer-readable medium of claim 27 wherein the level identifier is capable of designating a level from the set of levels including the second level, corresponding a page, and a first level corresponding to a document.
29. The computer-readable medium of claim 28 wherein the set of levels further includes a third level, above the first level, corresponding to a job.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A polish composition for coating a pharmaceutical solid dosage form comprising water, coating agent, and a film forming agent; wherein:
said water is present in an amount of about 80-99% of the total weight of the polish composition;
said film-forming agent is present in an amount of about 0.25-20% of the total weight of the polish composition and is a water soluble polymer selected from the group consisting of: water-soluble cellulose ethers, starches, disintegrants, dissolution aids, suspending agents, tablet binders, and combinations thereof;
said coating agent is present in an amount of about 0.01-5% of the total weight of the polish composition and is selected from the group consisting of: waxes, emollients, emulsifying agents, plasticizers, tabletcapsule lubricants, anti-caking agents, glidants, diluents, lubricants, solubilizing agents, opacifiers, colorants, and combinations thereof.
2. The polish composition of claim 1 wherein said film-forming agent is present in an amount of about 1-20% of the total weight of the polish composition.
3. The polish composition of claim 1 wherein said film-forming agent is selected from the group consisting of: polyvinylpyrrolidone, methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl methylcellulose, and combinations thereof.
4. The polish composition of claim 3 wherein said water-soluble cellulose ether is hydroxypropyl methylcellulose.
5. The polish composition of claim 3 wherein said water-soluble cellulose ether is hydroxypropyl methylcellulose having a viscosity of about 3-15 cps.
6. The polish composition of claim 1 wherein said coating agent is selected from the group consisting of: apple peel wax, avocado wax, bayberry wax, beeswax, candelilla wax, carnauba wax, jojoba wax, rice bran wax, lanolin wax, microcrystalline wax, mink wax, montan acid wax, montan wax, orange peel wax, ouricury wax, palm kernel wax, paraffin wax, glyceryl monostearate, magnesium stearate, talc, stearic acid, propylene glycol, glycerin, glyceryl triacetate, polyethylene glycol, triethyl citrate, dibuylsebecate, and combinations thereof.
7. The polish composition of claim 1 wherein said coating agent is carnauba wax.
8. The polish composition of claim 1 wherein said water is present in an amount of about 90-99% of the total weight of the polish composition.
9. The polish composition of claim 1 wherein said water is present in an amount of about 94-96% of the total weight of the polish composition.
10. The polish composition of claim 1 wherein said film-forming agent is present in an amount of about 4-5% of the total weight of the polish composition.
11. The polish composition of claim 1 wherein said coating agent is present in an amount of about 0.025-1% of the total weight of the polish composition.
12. The polish composition of claim 1 wherein said coating agent is present in an amount of about 0.05% of the total weight of the polish composition.
13. The polish composition of claim 1 wherein the solid dosage form is a tablet.
14. A polished pharmaceutical solid dosage form comprising a base pharmaceutical solid dosage form; and polish components forming a polished exterior surface of polished pharmaceutical solid dosage form, wherein:
the polish components comprise a filming-forming agent and a coating agent;
the film-forming agent comprises a water soluble polymer selected from the group consisting of: water-soluble cellulose ethers, starches, disintegrants, dissolution aids, suspending agents, tablet binders, and combinations thereof; and
the coating agent is selected from the group consisting of: waxes, emollients, emulsifying agents, plasticizers, tabletcapsule lubricants, anti-caking agents, glidants, diluents, lubricants, solubilizing agents, opacifiers, colorants, and combinations thereof.
15. A polished pharmaceutical solid dosage form comprising a base pharmaceutical solid dosage form; and polish components forming a polished exterior surface of the polished pharmaceutical solid dosage form, wherein:
the polish components comprise a filming-forming agent and a coating agent;
the film-forming agent comprises a water soluble polymer selected from the group consisting of: water-soluble cellulose ethers, starches, disintegrants, dissolution aids, suspending agents, tablet binders, and combinations thereof;
the coating agent is selected from the group consisting of: waxes, emollients, emulsifying agents, plasticizers, tabletcapsule lubricants, anti-caking agents, glidants, diluents, lubricants, solubilizing agents, opacifiers, colorants, and combinations thereof; and
the polished pharmaceutical solid dosage form is prepared using a polish composition of claim 1.
16. The polished pharmaceutical solid dosage form of claim 14 wherein the weight of the polish components is about 5% or less of the total weight of said polished pharmaceutical solid dosage form.
17. The polished pharmaceutical solid dosage form of claim 14 wherein the weight of the polish components is about 3% or less of the total weight of said polished pharmaceutical solid dosage form.
18. The polished pharmaceutical solid dosage form of claim 14 wherein the weight of the polish components is about 2% or less of the total weight of said polished pharmaceutical solid dosage form.
19. The polished pharmaceutical solid dosage form of claim 14 wherein the weight of the polish components is about 1-2% of the total weight of said polished pharmaceutical solid dosage form.
20. The polished pharmaceutical solid dosage form of claim 14 wherein said base pharmaceutical solid dosage form is a sugar coated pharmaceutical solid dosage form.
21. The polished pharmaceutical solid dosage form of claim 14 wherein said base pharmaceutical solid dosage form is a film coated pharmaceutical solid dosage form.
22. The polished pharmaceutical solid dosage form of claim 14 wherein said base pharmaceutical solid dosage form comprises one or more active agents selected from the group consisting of: conjugated estrogens and conjugated estrogens combined with medroxyprogesterone acetate.
23. The polished pharmaceutical solid dosage form of claim 14 wherein said base pharmaceutical solid dosage form comprises one or more conjugated estrogens in doses selected from the group consisting of: about 0.3 mgtablet, about 0.45 mgtablet, about 0.625 mgtablet, about 0.9 mgtablet, and about 1.25 mgtablet.
24. The polished pharmaceutical solid dosage form of claim 14 wherein said base pharmaceutical solid dosage form comprises one or more conjugated estrogens combined with medroxyprogesterone acetate in doses of conjugated estrogensmedroxyprogesterone acetate selected from the group consisting of: about 0.3 mg1.5 mg per tablet, about 0.45 mg1.5 mg per tablet, about 0.625 mg2.5 mg per tablet, and about 0.625 mg5 mg per tablet.
25. The polished pharmaceutical solid dosage form of claim 14 wherein the solid dosage form is a tablet.
26. A process of polishing a pharmaceutical solid dosage form comprising the steps of:
applying a polish composition of claim 1 to a heated base pharmaceutical solid dosage form; and
drying said base pharmaceutical solid dosage form with the polish composition; wherein the water from the polish composition evaporates to produce the polished pharmaceutical solid dosage form.
27. The process of claim 26 wherein the polish components of the polished pharmaceutical solid dosage form comprise 5% or less of the total weight of the polished pharmaceutical solid dosage form.
28. The process of claim 26 wherein the solid dosage form is a tablet.

1. Dental material comprising a radically polymerizable organic binder, at least one initiator for the radical polymerization and at least one accelerator for the radical polymerization, wherein both initiator and accelerator each have at least one radically polymerizable group.
2. Dental material according to claim 1, in which the binder contains monomers andor oligomers with two or more radically polymerizable groups.
3. Dental material according to claim 2, in which the binder contains at least one polysiloxane with radically polymerizable groups.
4. Dental material according to claim 2, in which the binder contains at least one dendrimer which has radically polymerizable groups.
5. Dental material according to claim 2, in which the binder contains at least one radically polymerizable crossliniking monomer.
6. Dental material according to claim 2, in which the binder contains exclusively radically polymerizable monomers andor oligomers with two or more radically polymerizable groups.
7. Dental material according to claim 1, which contains a photoinitiator.
8. Dental material according to claim 1, which contains as initiator at least one alpha-diketone, one azo compound, one peroxide, one benzildimethylketal, one benzoin ether, one dialkoxyacetophenone andor one trimethylbenzoyl phosphine oxide.
9. Dental material according to claim 1, which contains as accelerator an amine, a barbituric acid derivative or a sulfinic acid derivative.
10. Dental material according to claim 1, which additionally contains at least one UV absorber which has at least one radically polymerizable group.
11. Dental material according to claim 1, which additionally contains at least one inhibitor for the radical polymerization which has at least one radically polymerizable group.
12. Dental material according to claim 1, which additionally contains an anti-oxidant which has at least one radically polymerizable group.
13. Dental material according to claim 1, which contains a UV stabilizer and an inhibitor which both have one radically polymerizable group.
14. Dental material according to claim 1, which contains no non-radically polymerizable monomeric or polymeric constituents.
15. Dental material according to claim 1, which contains no solvent.
16. Dental material according to claim 1, which additionally contains filler.
17. Dental material according to claim 16, in which the filler is surface-modified with an adhesion promoter.
18. Dental material according to claim 17, in which the adhesion promoter has at least one radically polymerizable group.
19. Dental material according to claim 1, which additionally contains one or more pigments.
20. Dental material according to claim 19, which, apart from pigments and filler, contains exclusively components which have radically polymerizable groups.
21. Dental material according to claim 1, which contains
(a) 1 to 50 wt.-%, in particular 5 to 40 wt.-% of binder,
(b) 0.1 to 5.0 wt.-%, in particular 0.2 to 2.0 wt.-% of initiator,
(c) 0.1 to 5.0 wt.-%, in particular 0.2 to 2.0 wt.-% of accelerator in each case relative to the total mass of the material.
22. Dental material according to claim 21, which additionally contains (d) 0.01 to 3.0 wt.-%, in particular 0.05 to 2.0 wt.-% of inhibitor, relative to the total mass of the material.
23. Dental material according to claim 21, which additionally contains (e) 0 to 90, in particular 3 to 80 wt.-% of filler, relative to the total mass of the material.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method of treating a pathological condition in a patient in which endogenous 2-arachidonoylglycerol (2-AG) and endogenous 1(3)-arachidonoylglycerol or any other substrate metabolized by the monoacyl glycerol lipase (MGL) enzyme are involved comprising administering to said patient a therapeutically effective amount of a compound of formula (I):
in which:
A and X are, independently of one another, nitrogen or CH;
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy; and
R2 is an aryl group optionally substituted with one or more groups selected from halogen, methyl, trifluoromethyl, methoxy and trifluoromethoxy; or
a pharmaceutically acceptable salt thereof.
2. The method according to claim 1, wherein for the compound of formula (I):
A is nitrogen; and
X is CH.
3. The method according to claim 1, wherein for the compound of formula (I):
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy.
4. The method according to claim 1, wherein for the compound of formula (I):
R1 is phenyl, furan, thiophene or naphthalene, optionally substituted with halogen.
5. The method according to claim 1, wherein the compound is selected from the group consisting of:
5-(2-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
5-(3-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
5-(4-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-furan-3-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-thiophen-3-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-naphthalen-2-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone; and
(5-naphthalen-1-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone.
6. A method of treating a pathological condition in a patient in which endogenous anandamide or any other substrate metabolized by the Fatty Acid Amide Hydrolase (FAAH) enzyme is involved comprising administering to said patient a therapeutically effective amount of a compound of formula (I):
in which:
A and X are, independently of one another, nitrogen or CH;
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy; and
R2 is an aryl group optionally substituted with one or more groups selected from halogen, methyl, trifluoromethyl, methoxy and trifluoromethoxy; or
a pharmaceutically acceptable salt thereof.
7. The method according to claim 6, wherein for the compound of formula (I):
A is nitrogen; and
X is CH.
8. The method according to claim 6, wherein for the compound of formula (I):
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy.
9. The method according to claim 6, wherein for the compound of formula (I):
R1 is phenyl, furan, thiophene or naphthalene, optionally substituted with halogen.
10. The method according to claim 6, wherein the compound is selected from the group consisting of:
5-(2-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
5-(3-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
5-(4-chlorophenyl)1,2,3triazolo4,5-bpyridin-3-yl4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-furan-3-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-thiophen-3-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone;
(5-naphthalen-2-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone; and
(5-naphthalen-1-yl1,2,3triazolo4,5-bpyridin-3-yl)4-(3-trifluoromethylphenyl)piperazin-1-ylmethanone.
11. A method of treating a disease selected from the group consisting of an inflammatory disease, dizziness, eating disorders, metabolic syndrome, dyslipidemia, epilepsy, a sleep disorder, osteoporosis, an ocular condition, a pulmonary condition, a gastrointestinal disease, urinary incontinence, and bladder inflammation, comprising administering to said patient a therapeutically effective amount of a compound of formula (I):
in which:
A and X are, independently of one another, nitrogen or CH;
R1 is an aryl or heteroaryl group optionally substituted with one or more groups selected from halogen, (C1-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkoxy and halo(C1-C6)alkoxy; and
R2 is an aryl group optionally substituted with one or more groups selected from halogen, methyl, trifluoromethyl, methoxy and trifluoromethoxy; or
a pharmaceutically acceptable salt thereof.
12. The method according to claim 11 wherein the disease is an inflammatory disease.
13. The method according to claim 11 wherein the disease is dizziness.
14. The method according to claim 11 wherein the disease is selected from the group consisting of eating disorders, metabolic syndrome and dyslipidemia.
15. The method according to claim 11 wherein the disease is selected from the group consisting of epilepsy and a sleep disorder.
16. The method according to claim 11 wherein the disease is osteoporosis.
17. The method according to claim 11 wherein the disease is selected from the group consisting of an ocular condition and a pulmonary condition.
18. The method according to claim 11 wherein the disease is selected from the group consisting of a gastrointestinal disease, urinary incontinence and bladder inflammation.